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Abstract Obesity is a public health crisis. New methods
for amelioration of its consequences are required because it
is very unlikely that the social and economic factors driv-
ing it will be reversed. The pathological accumulation of
neutral lipids in the liver (hepatic steatosis) is an obesity-
related problem whose molecular underpinnings are
unknown and whose effective treatment is lacking. Here I
review how zebrafish, a powerful model organism long-
used for studying vertebrate developmental programs, is
being harnessed to uncover new factors that contribute to
normal liver lipid handling. Attention is given to dietary
models and individual mutants. I speculate on the possible
roles of non-hepatocyte residents of the liver, the adipose
tissue, and gut microbiome on the development of hepatic
steatosis. The highlighted work and future directions may
lead to fresh insights into the pathogenesis and treatment of
excess liver lipid states.
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Introduction
Pandemic obesity
The post-World War II rise in obesity continues unabated
[1], and it is clear that unanticipated and previously
unrecognized players in regulating energy homeostasis
must be discovered in order to combat the illnesses that
follow from calorie excess. Indeed, the current pharmaco-
logic armamentarium used in treating obesity’s attendant
illnesses (e.g., type 2 diabetes mellitus, hypertension,
dyslipidemia, atherosclerotic vascular disease) has seen
some of its gains negated by increased adiposity [2]. Thus,
there is pressing need for systematic and comprehensive
strategies for identifying novel genes that participate in all
aspects of energy homeostasis.
Special attention is needed for phenotypes of excessive
and ectopic lipid accumulation because of the poorly
understood reasons driving their development, and the
toxic effects of ectopic lipid accumulation on the whole
organism. More concretely, multiple lines of evidence
indicate adipose tissue has a finite capacity to safely store
neutral lipids. The spill-over of lipid metabolites from
over-stuffed adipocytes into the circulation leads to a host
of problems, including insulin resistance, hepatic steatosis,
intramyocellular liposis, accelerated atherosclerosis,
hypertension, and b-cell dysfunction [3]. While metabolic
syndrome and type 2 diabetes mellitus are the most
prominent manifestations of deranged lipid storage, it has
become widely recognized that obesity compounds or
causes several other conditions including high-output heart
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failure, restrictive lung disease, certain cancers, degenera-
tive joint disease, and chronic kidney disease [4].
Non-alcoholic fatty liver disease
Of the obesity-related disease processes just mentioned, it is
important to underscore that excessive liver accumulation of
lipids (hepatic steatosis) is present in a large fraction of obese
persons [5]. Alarmingly, hepatic steatosis is found in 30 % of
the general population, is present in nearly two-thirds
of patients with diabetes mellitus, and is seen in over 90 % of
very obese persons seeking weight-reduction surgery [6].
Comprehensive reviews cataloging what has been learned
from human genome-wide association studies on hepatic
steatosis [7, 8], and from monoallelic human disorders
marked by hepatic steatosis [8] leave us with a frustrating
picture of the genetic underpinnings of the inappropriate
accumulation of liver fat. First, the frequency of Mendelian
inheritance of hepatic steatosis is very low, and affected
persons often have striking, additional phenotypes not found
in the general population. Similarly, in large, prospectively
gathered cohorts of otherwise seemingly healthy adults only
one, repeatedly reproduced, robust association with a coding
polymorphism (I148M) in a lipid-modifying enzyme gene
PNPLA3 has been identified [9, 10]. Targeted deletion of the
Pnpla3 gene in mice does not cause hepatic steatosis [11, 12],
suggesting that the human polymorphism does not cause a
loss of function. In support of a dominant or gain-of-function
effect of the PNPLA3I148M mutation, overexpression of the
mutated human PNPLA3 (but not wild-type PNPLA3) cau-
ses increased mouse liver lipid accumulation [13]. This gain-
of-function observation reconciles an early report that
PNPLA3I148M has only modestly decreased triacylglycerol
hydrolase activity [9] (initially attributed to prevention of
triacylglycerol break-down) with more recent work showing
that PNPLA3I148M has increased lysophosphatidic acid
acetyltransferase activity relative to wild-type PNPLA3 (and
is thereby a major enzyme of triacylglycerol synthesis that
has only modest triacylglycerol hydrolase activity) [14].
Other associations between human polymorphisms and
hepatic steatosis have smaller attributable risk or are not
reproducible in more diverse cohorts [15, 16], leaving us
with a frustratingly incomplete picture of which genes
might contribute to this complex phenotype. This frustra-
tion mirrors the clinical heterogeneity of the disorder being
studied and the lack of effective treatments for it. Hepatic
steatosis is the first step in a spectrum of disorders that
encompasses inflammation (steatohepatitis), fibrosis (cir-
rhosis), and cancer (hepatocellular carcinoma) [17]. These
inter-related conditions are collectively referred to as non-
alcoholic fatty liver disease (NAFLD). There are limited
therapeutic options for permanently ameliorating hepatic
steatosis [18, 19] and there are no methods for reversing
hepatic fibrosis, or preventing hepatocellular carcinoma
due to NAFLD [20]. Indeed, the highest-quality clinical
trial shows very modest benefits for taking pioglitazone,
an insulin-sensitizing Peroxisome proliferator activated
receptor gamma agonist with multiple, long-term safety
concerns [19]. Paralleling this disappointing result are the
genome-wide association observations that while many
persons with NAFLD are obese and even have diabetes,
genes directly involved in insulin signaling have not been
implicated in the pathogenesis of this condition [7, 8]. Thus,
very high direct and indirect health costs are sustained by
inappropriate accumulation of neutral lipids in the liver and
little by way of pharmacologic agents is available to reverse
this.
Ultimately, the inability to treat NAFLD reflects a lack of
detailed knowledge of what triggers it [7], and what drives
its progression. The first step of NAFLD is the inappropriate
accumulation of triacylglycerol in the hepatocyte [21]. This
accumulation may be due to excessive de novo hepatic lipid
production, decreased hepatic secretion of very low density
lipoprotein particles, diminished b-oxidation of fatty acids
in the liver, more subtle defects in regulating energy
homeostasis including insulin resistance or central nervous
system nutrient sensing, a combination of these factors, or
some yet-to-be-appreciated mechanisms. Since each of
these possibilities could be amenable to therapeutic
exploitation, understanding their regulation is paramount.
Here I review the novel insights into hepatic lipid
metabolism gleaned from work with the model organism
Danio rerio, underscoring mechanistic studies that bring
new molecular players into focus, and highlighting new
areas that need to be explored.
Zebrafish: convergence of physiology, optics,
and genetics
Overview
The strengths of zebrafish as a model organism for study-
ing vertebrate development—facilitated by external
fertilization, relatively rapid development, optically trans-
parency, transgenic feasibility, and genetic tractability—
have been widely recognized for over two decades [22].
This long and successful track record of advances in
understanding vertebrate development through the analysis
of wild-type and mutant zebrafish has opened new avenues
of mechanistic research into multiple disease processes
[23]. Because it has the conventional vertebrate body plan
that includes central and autonomic nervous systems,
digestive organs, and adipose tissue, zebrafish is well suited




Lipid packaging and transport
The zebrafish utilizes a lipid-packaging machinery that is
conserved among metazoans to transport neutral lipids
from their sites of absorption (intestine and yolk) or syn-
thesis (liver) to peripheral organs. The molecular players
involved include apolipoproteins [25, 26] and apolipopro-
tein processing enzymes [27, 28]. These pathways have
been reviewed previously, and will not be rehearsed again
[24]; however, it is worth mentioning that following release
into the circulation, lipoproteins are modified in zebrafish
blood by a machinery that is also highly conserved in
evolution. For instance, zebrafish carry an ortholog of the
human Cholesteryl Ester Transfer Protein (CETP) gene. A
Cetp ortholog is frustratingly absent in commonly used
rodent models, rendering the study of atherosclerosis dif-
ficult in these systems since the animals are inherently
resistant to atherosclerosis [29]. The retention of the cetp
gene in zebrafish causes the circulating lipoproteins to
resemble human lipoproteins in abundance and composi-
tion, and this contributes to the susceptibility of zebrafish
to atherosclerosis when placed on a high-cholesterol diet
[30]. Furthermore, the deposition of subintimal cholesterol
can be monitored in real time, in live animals [31]. The
ability to study atherosclerosis in zebrafish should help in
examining the mechanisms underpinning the well-known
association of human NAFLD and atherosclerosis [32].
Dietary studies
In addition to propensity to atherosclerosis when placed
on high-cholesterol diets, zebrafish develop obesity,
hypertriglyceridemia, hepatic steatosis, and characteristic
adipocyte gene expression changes when over-fed their
normal diet [33]. These effects can be reversed by caloric
restriction. While complex metabolic phenotyping with
methods like calorimetry, glucose tolerance and insulin
tolerance testing, and stable isotope kinetic analysis is not
yet feasible in zebrafish, one potential strength of this
organism in generating diet-induced phenotypes is the
ability to screen potential therapeutic compounds in a
large-scale manner. High-throughput methods for per-
forming chemical screens in zebrafish are now available,
and it is conceivable that metabolic phenotypes like ame-
lioration of hepatic steatosis could be studied in such a
platform [34]. There is promising preliminary data in
support of this hope: diet-induced hepatic steatosis can be
ameliorated by high-lycopene and b-carotene-containing
tomato extract [35]. The molecular mechanism of this
reversal of hepatic steatosis in this model includes induc-
tion of genes encoding lipid oxidizing proteins. This study
of naturally occurring, complex extracts of vegetables
suggests that high-throughput screening of synthetic
chemical libraries may achieve similar, if not greater,
effects.
Along similar lines, a recent study of Liver X receptor
(Nr1h3) (Lxr) agonists finds that these drugs behave sim-
ilarly in zebrafish as they do in rodent pre-clinical models
[36]. Specifically, treatment of zebrafish larvae with Lxr
agonists cause hepatic steatosis, a finding that has frus-
trated drug development exploiting other beneficial
properties of Lxr activation [37]. Screening of new Lxr
modulators for hepatic steatosis in zebrafish might accel-
erate drug development.
Genetic screens
While the dietary and pilot pharmacological studies of
hepatic steatosis in zebrafish are encouraging, the identi-
fication of mutants with hepatic steatosis holds the
potential to identify completely unanticipated pathways
contributing to liver lipid metabolism, and possibly to
design of rational therapeutic strategies. To date, five
mutants with hepatic steatosis have been reported. The
mutated genes and phenotypes of the affected animals are
summarized in Table 1. One mutant was generated by
forward (unbiased) chemical mutagenesis [38]. Two are
from a library of lethal, retrotransposable element insertion
mutants [39, 40]. The fourth is a spontaneous retrotrans-
posable element insertion mutation found in some
commonly used laboratory strains [41]. The final is a
‘‘directed,’’ chemical mutagen-induced lesion in a gene of
interest to the investigators who described it [42].
Below, I summarize the major findings with each
mutant and discuss the implications of their identification










deposits can be imaged live
Heart
Liver
Lipid accumulation can be 
      imaged in situ
Pancreas
Principal islet of Langerghans (red)
   and the exocrine body (green)
Intestine
     Peristalsis and
   digestion of ingested 
material can be imaged live
Fig. 1 Anatomy of late larval zebrafish. Within the first week of life,
zebrafish larvae have functional circulatory and digestive systems.
The latter is under neuroendocrine control, as represented by function
pancreatic islets of Langerhans, which synthesis insulin and glucagon.
After 5–7 days of feeding (beginning 5 dpf), they accumulate lipids
in the visceral adipose depot. At this age, the animal remains
sufficiently transparent to allow for whole-mount imaging of internal
organs
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characterized during the late larval period, a time in
development when the liver already assumes a mature
architecture with numerous cell populations present and
active (Fig. 2). Two of these mutants have also been
examined for adult phenotypes [38, 41].
The first zebrafish hepatic steatosis mutant to be repor-
ted is foie gras (fgr) [39]. This mutant was identified in a
re-screening of a library of lethal mutations for liver size:
fgr mutants display hepatomegaly, marked by hepatocyte
nuclear degeneration and steatosis. The retrotransposon
insertion into the affected gene causes a very early trun-
cation of the encoded protein. The fgr mutant is
phenocopied by a translation initiation-disrupting antisense
morpholino oligonucleotide: fgr is a null mutation. The
function of the encoded Fgr protein was revealed in studies
using transfected mammalian cells and Drosophila
mutants. The Fgr protein is a higher metazoan-specific
component of the Trafficking Protein Particle Complex (it
is subunit 11, or TRAPPC11), a multimeric protein com-
plex involved in endoplasmic reticulum (ER)-to-Golgi
apparatus trafficking [43]. Interestingly, in Drosophila, the
orthologous gene is required for memory formation: the fgr
ortholog gryzun gene was identified in a screen for Dro-
sophila mutants with impaired memory formation. In this
study, the Gryzun protein was shown, again, to be an
important component of the TRAPP complex [44]; notably,
however, the human ortholog of TRAPPC11 (formerly
called C4orf41) was shown to be required for Golgi exit of
a secretory protein and for maintenance of Golgi archi-
tecture, but not for ER to Golgi transit of the model cargo
protein. Future studies should explore how loss of this
TRAPP component in zebrafish gives rise to hepatic stea-
tosis. Additional experiments are required to resolve where
and when this complex acts in the secretory machinery,
assessing specifically for cell-specific functions to this





































































































































































































































































































































































































































































































































































































































































































































































































Fig. 2 Histology of late larval zebrafish liver. The polarized hepa-
tocytes are sandwiched between the apical bile space in which the
cholangiocytes reside, and a basolateral space occupied by scattered
hepatic stellate cells and bounded by the vasculature. Within these
blood vessels, resident macrophages (Kupffer cells) reside. In hepatic
steatosis, the hepatocytes fill with cytoplasmic lipid droplets (red




lipoprotein particle egress disrupted by mutation of Trap-
pc11? If so, is there also defective intestinal secretion of
chylomicrons? More broadly, what is the role of endo-
plasmic reticulum stress in generating the hepatic steatosis
seen in fgr mutants, particularly as it relates to activation of
master transcription factors regulating lipid biosynthesis
[45]. Since the TRAPPC11 gene is broadly expressed,
compound phenotypes affecting other organs might pre-
clude full analysis in zebrafish mutants.
Another homozygous mutant reflecting this potential
pitfall of zebrafish screens (numerous phenotypes beyond
the desired hepatic steatosis) is ducttrip (dtp). The dpt
mutant was recovered in a chemical mutagen-induced
screen for defects in exocrine pancreatic [46]. This mutant
demonstrates normal early pancreatic differentiation, but
the ductal network and acinar marker expression were not
normal later in development. When the identity of the gene
responsible for this phenotype was determined by posi-
tional cloning, additional experiments were performed to
demonstrate that dpt mutants have hepatic steatosis and
liver degeneration [38]. The gene affected in this mutant is
ahcy, which encodes S-adenosylhomocysteine hydrolase,
an enzyme critical to generation of methyl donors for use in
numerous biological processes including nucleic acid,
protein, and lipid biochemistry. The dtp mutation induces
increased expression of genes encoding enzymes of de
novo lipogenesis and it activates an inflammatory reaction,
marked by increased Tumor necrosis factor-a production.
These results confirm nicely the evolutionarily central role
of methyl donor biology in normal liver function: numer-
ous studies in rodents employ a methionine and choline-
deficient diet to trigger a rapid and severe steatohepatitis.
Fortuitously, heterozygous adult dtp carriers show a stea-
tosis phenotype, indicating that while the homozygous
mutants have an intractable degeneration phenotype, the
haploinsufficient adults present an experimentally tractable
system for addressing biochemical and immunological
questions stemming from altered methyl donor biology.
Another demonstration that zebrafish livers employ
highly conserved molecular pathways to maintain homeo-
stasis is found in the hi559 mutant, which bears an
inactivating insertion in the cdipt gene [40]. This mutation
impairs phosphatidyl inositol (PI) synthesis, and lack of
this critical phospholipid (presumably) in the liver triggers
hepatocyte ER stress marked by activation of the unfolded
protein response and hepatocyte apoptosis by a mechanism
awaiting full elucidation. The mitochondrial morphology is
altered in hi559 mutant hepatocytes, but it is not known
whether this change affects fatty acid oxidation. Since
whole-larval PI levels are not altered prior to death, and the
exocrine pancreas appears normal in hi559 mutants, these
findings suggest that de novo PI synthesis in the hepatocyte
is critical to maintaining normal ER and mitochondrial
form and function. These findings add to an emerging lit-
erature on the interface of ER and mitochondrial
homeostasis and hepatic lipid metabolism [47], and prompt
further work examining signaling pathways requiring this
phospholipid for normal hepatic lipid regulation.
My group recently reported the positional cloning and
characterization of the red moon (rmn) mutant [41]. The
mutated gene encodes an integral plasma membrane protein
Slc16a6a that had not been characterized previously. We
found that this protein is a transporter for the major fuel of
fasting, b-hydroxybutyrate. As the fasted animal exhausts
its hepatic glycogen stores, fatty acids and amino acids
partially oxidized into acetoacetate and its reduction prod-
uct b-hydroxybutyrate. These ‘‘ketone bodies’’ are secreted
into the circulation in a 1:3 molar ratio. Unlike longer acyl
chain fatty acids, ketone bodies are suitable substrates for
use by the brain during periods of fasting. Mutation of this
hepatocyte exporter of b-hydroxybutyrate causes diversion
of liver-trapped ketogenic precursors into triacylglycerol, as
revealed by radiotracer analysis. Underscoring the impor-
tance of Slc16a6a to normal fasting physiology, previously
fed rmn mutants are more sensitive to death by starvation
than are wild-type larvae. Our unbiased, forward genetic
approach reveals a heretofore unrecognized critical step in
fasting energy metabolism: hepatic ketone body transport.
Since b-hydroxybutyrate is both a major fuel and a sig-
naling molecule in fasting [48], the discovery of this
transporter provides an opportunity to modulate circulating
levels of ketone bodies in metabolic diseases.
Future directions
Genetic background considerations
In our study, never-fed rmn mutants and their wild-type
siblings died between 12 and 13 days post-fertilization
(dpf). The animals were hybrids deriving from
AB 9 Singapore mutagenized animals that were subse-
quently crossed to the mapping WIK strains [49]. The
spontaneous rmn mutation was carried, we determined, by
the Singapore strain. This strain is evolutionarily related
most closely to the AB strain and the genomic reference
Tu¨bingen (Tu¨) strain [50]. Indeed, the Tu¨ isolate used in
the genomic assembly harbors the same retrotransposable
element insertion as our Singapore isolate does in the
slc16a6a gene. Our Tu¨ stock at the University of Utah
carries the rmn mutation, as well.
The rmn mutant’s pedigree raises an underappreciated
area of zebrafish investigation, namely the relative lack of
concern for genetic background needs to be revisited, par-
ticularly as more mutants are generated through high-
throughput methods. For instance, mutants derived from the
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Hubrecht Institute’s targeting induced local lesions in
genomes (TILLING) project have a complex genetic com-
position: the very large number of mutagenized males were
of the common Tupfel long fin (TL) strain, which we found
does not develop hepatic steatosis if never fed [28]. The TL
strain TILLING mutation carriers were outcrossed to the
common AB strain, or a hybrid AB 9 Mu¨nchen strain,
however [51]. This latter strain is not widely available, and
its genetic contribution might account for the fasting stea-
tosis at 11 dpf seen in wild-type siblings of serine/threonine
kinase 11 (stk11) [42]. The stk11 gene encodes Liver kinase
B1, a serine/threonine kinase upstream of the evolutionarily
central energy sensor AMP-activated protein kinase, whose
activation is required during fasting to mobilize glucose and
to suppress de novo lipogenesis and cholesterol biosyn-
thesis [52]. The stk11 mutants show hepatic glycogen
depletion and hepatic steatosis 7 dpf, a point in develop-
ment when the wild-type siblings show adequate glycogen
content and no steatosis. This is a gratifying result consid-
ering an extensive body of work done in mice with
mutations in the orthologous gene [53]. This particular
zebrafish mutant might be useful in a chemical screen for
modulators of the central AMP-activated protein kinase
energy-sensing pathway. Nevertheless, in contrast to our
work with the AB 9 Singapore 9 WIK wild-type siblings
of rmn mutants, the TL 9 AB (9Mu¨nchen, possibly) wild-
type siblings of stk11 mutants do develop hepatic steatosis
in the never fed state by 11 dpf. Thus, future studies of all
zebrafish mutants should keep genetic background consid-
erations in mind, and selected wild-type strains should be
meticulously examined prior to the initiation of a project.
Fortunately, new genomics data is emerging and this may
guide strain selection: recent work comparing the often-
mutagenized AB, and Tu¨ strains, a genuinely wild isolate
from Bangladesh, and the highly polymorphic (with regard
to microsatellite markers) WIK strains reveals that zebrafish
have very high levels of copy number variations (CNVs)
relative to higher vertebrates, and that the Tu¨ strain has the
highest CNVs of all strains examined [54]. These findings
make a strong case for using ‘‘composite’’ stocks of animals
derived from intercrossing of many individuals of different
strains in order to evenly distribute the number and type of
CNVs. Such a highly polymorphic, periodically refreshed
wild-type stock might minimize the effect of genetic
background on phenotypes, but it will require intensive
coordination to achieve across all laboratories using
zebrafish.
More screens or more phenotypes?
While forward genetics has identified new and potentially
‘‘drugable’’ pathways to modulate hepatic lipid mass, there
are several challenges to working with zebrafish that need
to be addressed if this system is to yield maximum fruit.
First, screens need to be followed by robust phenotypic
characterization. Mechanisms of metabolic derangements
will be uncovered only by using all the advantages of the
system listed above in tandem with new technologies that
allow for detailed characterization. Assays that are standard
in rodent models must become standard in zebrafish. Body
composition, sophisticated lipidomic approaches, and
classical physiological methods must be applied where
possible. Introducing bias into screens for viable mutants
(i.e., rejecting mutants that die as larvae) may lower the
overall yield of mutants recovered, but it may increase the
likelihood that such mechanistic biochemical experiments
can be performed. It is worth noting that live screening for
hepatic steatosis with new lipid reporters may accelerate
scoring of the phenotype and allow for more detailed
phenotypic characterization of lipid dynamics [55].
What else is in there?
By the end of the larval period, the zebrafish liver assumes
an anatomic configuration—hepatocyte polarization,
establishment and function of a biliary network, and vas-
cularization—reflective of mature organ function [56].
Beyond the hepatocytes, cholangiocytes, and endothelial
cells required to achieve this architecture, the liver has
additional cell types that contribute to lipid homeostasis
(Fig. 2). For instance, the innate immune reaction to
hepatocyte injury is mediated by the resident macrophage
population (Kuppfer cells), and these cells are central to the
development of steatohepatitis [57]. Fortunately, robust
fluorescent reporters of this cell type are established [58],
making live imaging to monitor their presence, number,
and (potentially) activation in NAFLD feasible. Similarly,
hepatic stellate cells, another cell type activated in response
to hepatocyte injury that is critical to the fibrotic response
at the far end of the NAFLD spectrum [59], can now be
investigated using the strengths of this model system [60]:
a powerful transgenic driver for labeling this population of
cells is available. These cells, like hepatic stellate cells of
higher vertebrates, store retinoids, and proliferate in
response to ethanol exposure. Thus, the zebrafish system
affords the opportunity to combine optical and genetic
properties to study critical steps of NAFLD pathogenesis
beyond the inciting event of steatosis.
Adipose tissue biology
Along similar lines, an integrated, ‘‘extra-hepatic’’ view of
the genes identified in mutants with hepatic steatosis must
be taken (Fig. 1). For instance, in those viable mutants with
hepatic steatosis, the consequences of the molecular lesion
on the adipose tissue need to be explored in a manner
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similar to that already achieved with diet-induced obesity
models. Also, because the ontogeny of zebrafish visceral
adipose has been described [61, 62], transgenic tools to
label these adipocytes for live imaging should be devel-
oped. Not only would such reagents allow interrogation of
adipocyte developmental biology, but they would provide a
window into simultaneous evaluation of multiple lipid-
handling organs. Finally, better tools for interrogating
insulin signaling (e.g., antibodies, transgenic reporter lines)
are also sorely lacking for this organism and need to be
prepared.
Gut microbes
In humans and in mice, the gut microbiome has profound
effects on nutrition [63]. An emerging appreciation for the
role of the gut microbiome in NAFLD makes it an attrac-
tive area of investigation [64]. The core microbiome of the
zebrafish intestine has been defined [65]. Thus, this model
organism should be used to explore the form and function
of the gut microbiome on nutrient sensing and processing
using the optical, genetic, and physiological properties
highlighted above. Specifically, the interplay of gut
microbes with the development or amelioration of hepatic
steatosis should be examined in future studies.
Conclusions
The zebrafish is emerging as a powerful system for dis-
covering and investigating new pathways that contribute to
hepatic lipid metabolism and exploring the mechanisms of
NAFLD. The identification, cloning, and analysis of sev-
eral mutants with hepatic steatosis demonstrate that this
approach will uncover important biological players. A
combination of new genetic, optic, and physiologic tools
and approaches should yield still more novel insights.
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